$JHX

Skelly Jonathan sold $2.0M of JHX

Skelly Jonathan (Pres. James Hardie NA) sold 65,000 shares of James Hardie Industries plc (JHX) at an average of $30.46 ($30.45–$30.46, $1.98M total) across 2 trades on 2026-08-25.

Original reporting
SEC EDGAR · Skelly Jonathan
Published Aug 27, 2026, 11:14 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 27, 2026, 11:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$JHX
Bearish
medium confidence
Mentioned
$JHX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$JHXBearishLow
01

Why it matters

Direct insider sell provides fresh data for traders assessing JHX.

02

Market read

New insider sale may influence short-term trading sentiment for JHX.

03

What to watch

Sale could be part of a pre-arranged liquidity plan unrelated to company fundamentals.

Relevance 6/10Novelty 7/10Timing: filed today

Background

Form 4 filing discloses insider transactions to the SEC.

Company-level read

Ticker impact

$JHXBearishMedium confidence
Context

Officer Skelly Jonathan sold 65,000 shares for $1.98M, reducing his stake to 309,906 shares.

Expected impact

Potential short-term pressure on JHX price.

Evidence & confidence

Officer-level insider sale of nearly $2M is material; market may interpret as a negative signal.

Market effects

Minimal impact on building materials sector.

Limited to investors tracking JHX.

Low

Counterpoint

Insider may be diversifying; sale does not necessarily indicate negative outlook.

Key entities

  • James Hardie Industries plc

    Building materials manufacturer listed on NYSE under ticker JHX.

  • Skelly Jonathan

    President of James Hardie North America.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$JHXMed

James Hardie upgrades FY27 cash flow guidance but not earnings, shares dip 5%

James Hardie (JHX) raised its FY27 free cash flow guidance by 20% to ~US$600M, but shares fell 5% as sales and earnings guidance remained unchanged. The company expects to achieve US$125M in cost synergies a year ahead of schedule. Management stated the guidance does not assume a housing recovery. FY26 free cash flow was US$425M, after deal and integration costs of ~US$207M.